Welcome to our dedicated page for Barinthus Biotherapeutics plc SEC filings (Ticker: BRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Barinthus Biotherapeutics plc filings document material events, security structure, governance matters and clinical disclosures for a clinical-stage biopharmaceutical issuer organized in England and Wales. Recent Form 8-K reports describe American Depositary Shares listed under BRNS, with each ADS representing one ordinary share, along with capital-structure disclosures and emerging growth company status.
The company’s regulatory record also covers shareholder voting matters, material agreements, operating and financial results, clinical or regulatory updates related to its immunotherapy programs, and Nasdaq listing-compliance notices. These filings provide formal disclosure around the company’s ADR program, ordinary-share structure, board and governance matters, and public-company reporting obligations.
Barinthus Biotherapeutics plc reported the final voting results from its court and general meetings on a proposed Scheme of Arrangement connected to a Scheme Transaction. At the Barinthus Court Meeting, 40,848,893 Scheme Shares were entitled to vote and 24,713,109 were present, establishing a quorum. A majority in number of holders, representing 99.98% by value of Scheme Shares voted, approved the Scheme, with 0.02% by value voting against.
At the Barinthus General Meeting, 40,848,893 ordinary shares were entitled to vote and 24,714,119 were present, also establishing a quorum. Holders of ordinary shares cast 99.98% of votes in favor and 0.02% against the special resolutions described as the Scheme Implementation Proposal, with 10 abstentions and no broker non-votes. All matters submitted to a vote at both meetings were approved.
Barinthus Biotherapeutics plc filed an initial insider ownership report for Douglas J. Swirsky, who serves as Principal Accounting Officer. This Form 3 filing establishes his status as an executive officer and discloses that there were no reportable share transactions or derivative positions included in this submission.
Barinthus Biotherapeutics plc reported sharply improved results for the three months ended March 31, 2026 while advancing its planned all‑stock merger with Clywedog Therapeutics. Net loss attributable to shareholders was $5.5 million, compared with $19.6 million a year earlier, driven mainly by lower operating expenses.
Research and development spending fell to $3.6 million from $8.3 million, reflecting the strategic shift toward autoimmune and inflammatory diseases and wind‑down of legacy infectious disease and oncology programs, while continuing the Phase 1 AVALON trial of lead celiac candidate VTP‑1000. General and administrative costs dropped to $2.5 million from $12.6 million, aided by foreign exchange gains and prior cost actions.
Cash, cash equivalents and restricted cash totaled $67.2 million as of March 31, 2026, with management expecting this to fund standalone operations for at least 12 months. The Clywedog merger structure includes a U.K. court‑sanctioned scheme of arrangement, creation of new parent Topco, potential self‑tender of up to $27.0 million of Topco common stock, and exchange ratios that will be finalized before closing.
Barinthus Biotherapeutics reported a first quarter 2026 net loss attributable to shareholders of $5.5 million, or $(0.14) per share, improving from a $19.6 million loss, or $(0.49) per share, a year earlier. Operating expenses fell sharply as research and development dropped to $3.6 million and general and administrative costs to $2.5 million, reflecting portfolio refocusing and workforce reductions.
Cash, cash equivalents and restricted cash totaled $67.2 million as of March 31, 2026, and the company expects these resources to fund operations for at least 12 months under its standalone plans. Barinthus is progressing its proposed mid-2026 merger with Clywedog Therapeutics, after which the combined company will be renamed Clywedog Therapeutics Holdings, Inc. and is expected to trade on Nasdaq under the ticker CLYD, with an estimated cash runway through 2027 supported by existing and new investors. The Phase 1 AVALON trial of core asset VTP-1000 in celiac disease is advancing, with multiple ascending dose data expected in the second half of 2026.
Barinthus Biotherapeutics plc is seeking shareholder approval to implement a scheme of arrangement under which Beacon Topco, Inc. (Topco) will acquire Barinthus and combine with Clywedog Therapeutics, Inc. The Scheme would convert each Barinthus ordinary share into between 0.1 and 0.166667 Topco common shares (final ratio to be set by the Barinthus Board) plus cash for fractions, and Topco expects to issue approximately 20,678,394 shares of Topco Common Stock at closing assuming a Self-Tender Offer of $20.25M (75% of a possible $27,000,000). Upon closing, holders of Barinthus shares are expected to own approximately 34% of Topco on a fully diluted basis and Clywedog stockholders approximately 66%, the combined company intends to list on Nasdaq under the symbol CLYD, and Barinthus ADSs will cease trading on the Nasdaq Global Market. The Scheme requires Court sanction and shareholder approval and is subject to the conditions, adjustments and timing set forth in the Merger Agreement and related documents.
Barinthus Biotherapeutics plc has appointed Douglas Swirsky as its new Chief Financial Officer and principal accounting officer, effective May 1, 2026. Swirsky, age 56, brings over 25 years of experience in finance and leadership roles across several biotechnology and pharmaceutical companies.
The company entered into a master services agreement with Grand Strand BioAdvisors LLC, under which Swirsky will provide CFO services for a fee of $20,000 per month. Barinthus will provide directors’ and officers’ liability insurance and indemnification on terms comparable to its other officers, and the filing states there are no related-party or family relationships requiring additional disclosure.
International Generosity Foundation Trust, a Florida-based non-profit trust, reported beneficial ownership of Barinthus Biotherapeutics plc common stock. It holds 2,734,189 shares, representing 6.7% of the outstanding common stock, with sole voting and sole dispositive power over all of these shares.
The trust acquired the position through a mix of purchases funded by its working capital and transfers or contributions it received, reflecting both investment and charitable purposes. It states it may buy more shares or sell some or all holdings over time, including to support its charitable activities, but reports no transactions in the issuer’s securities during the past 60 days and no special contracts or arrangements relating to the stock.
Barinthus Biotherapeutics plc reports that Gemma Jones, who serves as its principal accounting officer through CFGI, has notified the company she will step down from that role effective April 30, 2026.
The company includes extensive forward-looking statements language, noting that the planned departure and related timing are subject to risks and uncertainties tied to its development pipeline, regulatory environment, restructuring efforts and funding. It refers readers to its Annual Report on Form 10-K for the year ended December 31, 2025 and other SEC filings for additional risk factors.
Barinthus Biotherapeutics plc files its annual report highlighting a major strategic pivot toward autoimmune and inflammatory diseases and a planned all-stock merger with Clywedog Therapeutics, Inc. The company is centering development on its SNAP‑TI tolerance platform and lead celiac candidate VTP‑1000.
Barinthus launched a restructuring in January 2025, prioritizing immunology and inflammation, deprioritizing infectious disease and oncology assets like VTP‑300, and reducing its workforce by approximately 65% while closing its U.K. site to extend its cash runway into 2027. VTP‑1000 showed dose-dependent pharmacologic effects and was well tolerated in a Phase 1 single-ascending-dose study, with multiple-ascending-dose data expected in the second half of 2026.
The report details encouraging Phase 2 data for legacy hepatitis B candidate VTP‑300, extensive global IP around the SNAP platforms, and key license and collaboration agreements with Oxford University Innovation and the NIH. It also outlines substantial clinical, regulatory, financing, integration and Nasdaq listing risks, including the possibility the contemplated Clywedog combination is delayed or not completed.
Barinthus Biotherapeutics reported a 2025 net loss attributable to shareholders of $66.5M, or $(1.64) per share, versus a $61.1M loss in 2024. Revenue fell to zero from $15.0M of license revenue the prior year.
Research and development expenses declined to $25.6M from $42.2M as the company refocused on immunology and inflammation and deprioritized infectious disease and oncology “legacy” assets. General and administrative expenses rose to $40.8M from $29.7M, driven mainly by higher foreign exchange losses and professional fees related to strategic activity.
Barinthus recorded a $4.7M impairment of intangible assets after the anticipated valuation implied by its definitive merger agreement with Clywedog came in below the carrying value of net assets. Cash, cash equivalents and restricted cash were $71.9M as of December 31, 2025, with management expecting standalone resources to fund operations for at least 12 months.
The company is pursuing an all-stock combination with Clywedog Therapeutics, targeting a closing in the second quarter of 2026 and a new NASDAQ listing as “CLYD.” The combined company is expected to have a cash runway through 2027 and a diversified pipeline in metabolic and autoimmune diseases, including Barinthus’ VTP-1000 celiac program and Clywedog’s diabetes candidates.